Orbital Therapeutics strives to provide health solutions through the use of RNA-based treatments and medicines.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
04/26/2023 | Series A | $270MM | $xx.xx | $705.88MM | ARCH Venture Partners, Andreessen Horowitz, Newpath Partners, Abu Dhabi Growth Fund, Redmile Group, Exor N.V., Invus, Moore Strategic Ventures, iGlobe Platinum Fund Group, Casdin Capital, Agent Capital, Alexandria Venture Investments, Rellim Capital Management, Heritage Medical Systems | |
Price per Share
$xx.xx
Shares Outstanding
180,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
ARCH Venture Partners, Andreessen Horowitz, Newpath Partners, Abu Dhabi Growth Fund, Redmile Group, Exor N.V., Invus, Moore Strategic Ventures, iGlobe Platinum Fund Group, Casdin Capital, Agent Capital, Alexandria Venture Investments, Rellim Capital Management, Heritage Medical Systems
|
||||||
09/07/2022 | Series Seed | $103MM | $xx.xx | $260.59MM | ARCH Venture Partners, Andreessen Horowtiz, Newpath Partners | |
Price per Share
$xx.xx
Shares Outstanding
103,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
ARCH Venture Partners, Andreessen Horowtiz, Newpath Partners
|